The application of programmable shunts in the management of hydrocephalus in pediatric patients

Area of Science:

• Neurosurgery
• Pediatric Neurology
• Biomedical Engineering

Background:

• Hydrocephalus is a common neurological condition in children, characterized by abnormal accumulation of cerebrospinal fluid within the brain's ventricles.
• Programmable shunts offer adjustable cerebrospinal fluid (CSF) diversion, allowing for non-invasive pressure modifications.
• Effective management of pediatric hydrocephalus is crucial to prevent cognitive and developmental impairments.

Purpose of the Study:

• To evaluate the efficacy and outcomes of using programmable shunts in pediatric hydrocephalus treatment.
• To identify the primary indications for programmable shunt implantation in children.
• To analyze factors influencing treatment success and the need for shunt revisions.

Main Methods:

• Retrospective analysis of 54 pediatric patients who received Medtronic™ Strata II programmable shunts for hydrocephalus between 2013 and 2023.
• Exclusion of patients with tumor-related hydrocephalus.
• Evaluation of indications for de novo versus secondary shunt implantation and subsequent outcomes.

Main Results:

• Programmable shunts were implanted de novo in 40.74% and secondarily in 59.26% of patients.
• Indications included enlarged ventricles (de novo) and overdrainage syndrome (secondary).
• 44.44% required reprogramming; 24.07% needed revisions, with higher rates in posthemorrhagic hydrocephalus cases. 10-year revision-free rates were 90.9% (de novo) vs. 59.9% (secondary).

Conclusions:

• Programmable shunt implantation is an effective treatment modality for pediatric hydrocephalus.
• Initial valve settings were often sufficient, minimizing the need for adjustments.
• Secondary implantation and posthemorrhagic hydrocephalus etiology are associated with increased revision rates.